 Það er verki sem ekki að vædu fyrir að hérum. Sveit að eðað að að í hverhag þgur, eðað að sjegum að því að áfona, það vef á þaræ Country Hulcar. Nu að því að var enn ennæ á það bæg og það. Þó, The first one is coming to me. I don't know much about you guys, but, you know, okay. Again it's coming. Just try to correct this one. See a few words about the statistics of the NN20. It came around 260 presentations, around 68 new invite presentations, ...to run the conference, because actually they will know the proper facilities, they hear us a lot, so just to remind you what I said in the beginning of this conference on Tuesday morning how it was in 2019, few people are present, almost 29% ...and year by year again is here this time, all of the people are in life mode, less in virtual mode, but we hope next year to be even better, and what you believe is that some number of people connected from virtually will be remain the next years, this new tool actually, ...some people who used to come for one day presentation for example, or some people who there is no other possibility to participate, it will make this type of connections. ...but in any case you have to keep in mind that people can try to support two conferences, one which is the real as you can see here, and the other is visual, many people work on this one during the days in order to support this one, and of course during this breakdown of electricity you understand how much mass occurred. You succeed ourself here, but it's sure that in many other places in the planet and nowadays they run life in the virtual applications, so just to remind you the full, the five works on the field, the NN22, it was the first one on nanoelectronics, the convention electronics actually, this is based on organics, organics and productors, and all these specific things on communications, photonics and nano energy, the works of nanobio material, bioaspects and polymers are introduced, maybe also introduced and discuss some aspects not only on organic and organics and productors organic, ...and then it was the works of number three, which it was the last one closely all this conference, the NN22. The subjects we discussed in the last session, but also in the morning session we have this conference, we discuss the meat of nanotechnology with modern biology and also 3D printing as it was in the last presentation, the works of four which was a new one started less than 10 years ago, talking about biosensors and bioelectronics is a works of force running in parallel with NN, with nanomedicin, and with each way the other operas, and the last one was on two dimensional materials, productive materials or other metallic materials like graphene synthesis and other decay. So, just to remind you and in parallel to say that many thanks to all these people here, these people in professors and people from the industry with the keynotes, keynotes big talks, and of course all these people from academia, research institution and industry, who give us the opportunity to hear from them the last results and the progress in the field. And thanks to some pictures taken during the days, also I see also Nicolás Erre, he gave the opportunity our presentation, some of them to be in life and life is going to see many people and some of you could say we are not present. So this is some pictures during the lectures or during the event, many thanks to people and our major who presented it and he is giving me the welcome and support every year. Several pictures taken during the age of 2022, many thanks to people from exhibitors and researchers who presented the results of operas and of course some pictures just to remind you on Tuesday night, the place is official Galá dealer. Dancing, OK, as you can see here, people without any order they decide to, I don't remember which sign is this one, but it's a very good picture. I don't know the picture of this one, but people dancing spectacularly like something this, OK. I would also like to thank for the committee, the rest of the committee of this conference, professor of Angiúáno and from Bologna University and the professor of English from Cornell. Professor of Pomófros Bôsíðið þí er þí aðð er því að þí þessars að því húðir þvíðin á Það þið ervoðin lássandi, professor Silvæð, tígvóðið þaðsim að þið að þið að þið á því að þið að þið að þið að þið að þá þið að á því að þið að þið að þið að á hvós kristófors, fyrir fyrir fyrir fyrir fyrir fyrir fyrir, ok, ok, you see many thanks to Christófors, he is the head of this conference. Ok, as I mentioned earlier, many thanks to all the people from the sponsors and especially the exhibitors gave us the opportunity to see tools, results to discuss with them during the days and during the breaks and now coming to it just to remind you that we have these publications so all of us, with this idea after everyone to publish in materials today proceedings then the extended day is 30 of August and this material calendar for 2023 and then we will be taking place on July 4th to July 7th 2023 Tuesday to Friday again and then we will start first of July with the schools and coming now to hours, the last part of this conference just to remind that the committee with chairman, professor, the UN especially is, the UN professor you coordinate a team of two, four, six persons in order to decide where we go from this 200 to 200, let's say the order presentation the post presentation, the award for the awards so the awards goes to the committee here you are here professor, I showed him a couple of articles but we have the coordinator here ok ok, you are ready to announce, do you have the hours? ahhh, ok also is inside ok, also is inside, don't worry we have the results and now that's one so sorry, what's that? how's happening? this is from yesterday have the virtual, this is real, I have the two real ones so you see the electricity but hopefully this will make great a problem so in recognition of best oral presentation goes to Maximilian Heiko Burk he is online, sorry, he is online you will keep this one because Mr. Heiss and later in the photo you will see I hope the next one is going to be the best poster presentation in this court is Rafa Oman ok, ok, so let's come in ok, what's that? just a moment, just a moment you keep the other one ok it's here, they want more pictures they should have the film now the only time, nobody will see thank you so much for the view, I'm here ok, please, all together ok, congratulations so it's from Nanomedicin ok, congratulations so, thank you very much by this you arrive in the end of all this people from the team that especially in this ladies here you can see the reception this is Dimaraki and Mr. Dimaraki the other people that I know but I don't know what they are because this event is external for many people in the world many thanks to people from Kópeán and our students from Master's degrees and of course many thanks to hotel people from Porto Palá people who helped a lot with hospitality and they support that during the days so by this, thank you and I hope to enjoy the meetings here in the city as well I hope to put a nice way back to come and I hope to see you soon somewhere on person or next year, thank you very much my name is Kascusulis I'm a professor of virology and biotechnology and head of the Department of Pathopology Sciences at Louisiana State University in Veterinary Medicine as well as the Stanley Scott Cancer Center Medical School in New Orleans so, what did you talk about here at this conference? so, I was very pleased in this conference for the nanotechnology 2022 part of the nanomedicine sessions to present some of our work on the use of viruses for cancer treatment the talk focused specifically on how we use herpesyplex virus as a vector not only for a therapeutic vaccine for melanoma and breast cancer but even more importantly as a prophylactic vaccine we had proof of principle a recent publication on this particular subject that we use this vaccine strategy to prophylactically to protect against melanoma and breast cancer so, that would be amazing if you have a vaccine to protect against cancer could it be against all kinds of other cancers too? yeah, we already have examples of successful vaccines for instance, against papyroma viruses the Gardasil vaccine that has been used now extensively to prevent any cervical cancer for women that may be created 23 years past their infection with papyroma viruses there's also efforts right now for prostate cancer vaccine doesn't work as well as it should but I think the principle of vaccinating against the specific cancers it's already proven and it's just a matter of time that we find the right neoantigens these are the changed proteins that could be used to successfully combat different types of cancer does it have anything to do with what they've been doing with the mRNA is that nanotechnology? so, it is nanotechnology in a sense there are actually efforts to use mRNA vaccines for cancer purposes for vaccines against cancer as well as subunivaccins purified proteins the difference between viral vector systems is that you could do multiple things include multiple neoantigens so you have a much better chance you could also provide other inhibitors whether it be microRNAs or any other ways to shut down specific mesigling pathways to really prevent cancer treatment is it correct that you need to have something that's very immunizing to be able to vaccinate strongly against it? yeah, and this is correct the current idea is to find neoantigens these are really changed antigens but also they need to be antigens that can generate a strong immune response that could eliminate certain tumor cells when they first are created obviously, with the advent of now molecular genetics the ability for us to sequence the entire genome we only have the genome we have the transcriptome we have the metabolome, the proteome all this information together can be used to create vector vaccine approaches to combat cancer at multiple points and I think that would be the ultimately successful as we know right now combination therapies and personalized medicines personalized drug therapies towards cancer is actually a solution and I think ultimately that's what will happen the vaccine therapeutic approach would be one in combination with others perhaps some anti cancer drugs chemotherapeutics that could be used in combination to create a much more efficacious strategy to combat cancer last time we did a video I think you mentioned the word adenovirus is that still in your thinking? yes, so adenovirus right now is also used as a vector approach for cancer in an immunotherapy approach this is one of the viruses the difference between herpes viruses is that herpes viruses already have two successful products on the market right now one is the tvek which is the product generated produced by AMGEM which is really used to combat melanoma right now and also another one which is really another herpes simplex virus G407 which now has been licensed for use for the treatment of glioma in children and adults in Japan and it will be a matter of time that will be also licensed in the US and throughout the world so we do have two successful herpes viruses to combat these very important cancers adenoviral studies have also been going there are also a number of other viruses that are being used right now in phase 1, phase 2 trials to combat different types of cancers so it's three years ago around we did the last video so you have like the company that's been progressing and you're bringing you say it's successful so you're bringing this to market for sure and how soon? well the the viral vector that we're using is being now tested as a vaccine against herpes viruses that will be tested in England through a phase 2 combined clinical study that particular study will actually pave the way for the use of the virus for other purposes including cancer and we hope that ultimately we'll move on to a phase 1 trial for the treatment of most likely breast cancer as soon as possible and with all the stuff that's been happening in the world the last 2-3 years is it giving you an extra push and helping you get all this out? well you know cancer is one of the most important diseases a lot of people suffer there are different heterogeneous cancers of all types and I think you know immunization we have combated diseases like measles and the mumps and polio and of course papillomoviruses and cancer we have combated coronaviruses using vaccines so why not even cancer and I think this is the era a recent article in New York Times highlighted this fact that we are really in the era where cancer vaccines will be produced and hopefully will be very efficacious I don't know if it's correct to say that it's been hard to immunize with the coronavirus and all the different variants and everything how do you think it's immunizing what you're working towards compared to the coronavirus? so the basic principle is that vaccines some of them are extremely effective they eliminate the virus or the cancer 100% but most of the these approaches are really actually synergistic to our immune system so part of the idea and what's happening with current coronavirus vaccines is not necessarily to eliminate the coronavirus but they reduce the viral load and the viral load is at that level that then the immune system can actually successful combat it the same thing would be true for cancer vaccines so what we hope is vaccines would be able to assist the immune system in fact these vaccines are immunomodulatory that means they enhance the immune system as we know now with cell cycle check inhibitors with a lot of these boosting adjuvant that are used for cancer vaccines the idea is to really boost a modulated immune system to successful combat these cancers and how much we combat the the problem people have with different kind of herpes how much are you targeting to bring a solution to that? so the vaccines for herpes right now that we are working on would be tested for both therapeutic and prophylactic therapeutic for those people already infected with herpes simplex type 2 and suffer a lot this is actually the primary target of the company that pursues these rational vaccines for which I'm consulting and ultimately that type of vaccine will also be used prophylactic in much younger ages to prevent the initial infection by herpes viruses that will help a lot in the use of these viruses as a vectors for other vaccines where there would be malaria influenza corona as well as on colitis immunotherapeutics for various cancers as a final message could you be optimistic in terms of maybe being a vision where there is no more herpes there is no more cancer as it can happen I think we are very optimistic I would say highly optimistic we could really reduce herpes viruses to a very mild infection and I think that we use the virus herpes viruses as a vector to successively combat a little number of important diseases not only herpes but also malaria influenza COVID-19 and other pathogens as they come through but when you use herpes as a vector it's not a negative thing for the person who didn't have herpes before so these viruses have been engineered to be 100% safe and attenuated they do not get into nerves they do not cause any disease whatsoever and in fact the very fact that is used right now for cancer treatment that in humans we know that it will work Alright, thanks a lot Thanks